Xponance Inc. Sells 15,068 Shares of DaVita Inc. (NYSE:DVA)

Xponance Inc. reduced its position in DaVita Inc. (NYSE:DVA) by 55.0% in the 4th quarter, Holdings Channel reports. The firm owned 12,314 shares of the company’s stock after selling 15,068 shares during the quarter. Xponance Inc.’s holdings in DaVita were worth $1,290,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. Czech National Bank boosted its position in shares of DaVita by 43.7% during the 3rd quarter. Czech National Bank now owns 9,412 shares of the company’s stock valued at $890,000 after acquiring an additional 2,863 shares in the last quarter. Asset Management One Co. Ltd. grew its stake in shares of DaVita by 3.2% in the 3rd quarter. Asset Management One Co. Ltd. now owns 21,759 shares of the company’s stock valued at $2,057,000 after purchasing an additional 672 shares during the period. Handelsbanken Fonder AB raised its holdings in shares of DaVita by 21.2% in the 3rd quarter. Handelsbanken Fonder AB now owns 8,000 shares of the company’s stock worth $756,000 after buying an additional 1,400 shares in the last quarter. Robeco Institutional Asset Management B.V. boosted its stake in DaVita by 175.4% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 50,343 shares of the company’s stock valued at $4,759,000 after buying an additional 32,062 shares in the last quarter. Finally, FinTrust Capital Advisors LLC grew its position in DaVita by 242.3% in the third quarter. FinTrust Capital Advisors LLC now owns 712 shares of the company’s stock valued at $67,000 after acquiring an additional 504 shares during the period. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Stock Performance

Shares of DaVita stock opened at $132.75 on Thursday. The company has a debt-to-equity ratio of 6.65, a current ratio of 1.19 and a quick ratio of 1.13. The firm has a 50 day simple moving average of $131.63 and a 200 day simple moving average of $110.00. DaVita Inc. has a fifty-two week low of $71.51 and a fifty-two week high of $141.54. The firm has a market cap of $11.64 billion, a P/E ratio of 17.94, a P/E/G ratio of 1.19 and a beta of 1.04.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, February 13th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.53 by $0.34. DaVita had a return on equity of 64.42% and a net margin of 5.70%. The company had revenue of $3.15 billion during the quarter, compared to analysts’ expectations of $3.01 billion. During the same period last year, the firm earned $1.11 EPS. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. Sell-side analysts predict that DaVita Inc. will post 9.23 earnings per share for the current fiscal year.

Analysts Set New Price Targets

DVA has been the subject of a number of analyst reports. TheStreet raised DaVita from a “c+” rating to a “b-” rating in a report on Wednesday, February 7th. UBS Group boosted their price target on shares of DaVita from $113.00 to $134.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. Barclays initiated coverage on shares of DaVita in a report on Wednesday, March 6th. They set an “equal weight” rating and a $133.00 price objective for the company. StockNews.com cut DaVita from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 16th. Finally, Truist Financial boosted their price objective on DaVita from $130.00 to $135.00 and gave the stock a “hold” rating in a research note on Tuesday, February 20th. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.50.

Insiders Place Their Bets

In other news, insider Kathleen Alyce Waters sold 11,285 shares of the firm’s stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $120.73, for a total value of $1,362,438.05. Following the transaction, the insider now owns 81,297 shares of the company’s stock, valued at approximately $9,814,986.81. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other DaVita news, insider Kathleen Alyce Waters sold 11,285 shares of the company’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $120.73, for a total transaction of $1,362,438.05. Following the completion of the sale, the insider now owns 81,297 shares in the company, valued at approximately $9,814,986.81. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Javier Rodriguez sold 67,603 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $126.11, for a total value of $8,525,414.33. Following the completion of the transaction, the chief executive officer now owns 488,697 shares in the company, valued at $61,629,578.67. The disclosure for this sale can be found here. In the last three months, insiders sold 134,540 shares of company stock valued at $16,551,071. 1.40% of the stock is currently owned by insiders.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.